Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Jan 2011 - J. Clin. Oncol.; 29(3):1527-7755 [PMID:21149657]
[Okada H] [Kalinski P] [Ueda R] [Hoji A] [Kohanbash G] [Donegan TE] [Mintz AH] [Engh JA] [Bartlett DL] [Brown CK] [Zeh H] [Holtzman MP] [Reinhart TA] [Whiteside TL] [Butterfield LH] [Hamilton RL] [Potter DM] [Pollack IF] [Salazar AM] [Lieberman FS]

Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.
Feb 2009 - Clin. Vaccine Immunol.; 16(2):1556-679X [PMID:19038780]
[Whiteside TL] [Piazza P] [Reiter A] [Stanson J] [Connolly NC] [Rinaldo CR] [Riddler SA]

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
Feb 2008 - J Transl Med; 5:1479-5876 [PMID:18093335]
[Okada H] [Lieberman FS] [Walter KA] [Lunsford LD] [Kondziolka DS] [Bejjani GK] [Hamilton RL] [Torres-Trejo A] [Kalinski P] [Cai Q] [Mabold JL] [Edington HD] [Butterfield LH] [Whiteside TL] [Potter DM] [Schold SC] [Pollack IF]

Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
Feb 2008 - Clin. Vaccine Immunol.; 15(2):1556-679X [PMID:17942609]
[Connolly NC] [Whiteside TL] [Wilson C] [Kondragunta V] [Rinaldo CR] [Riddler SA]

Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects.
Aug 2007 - AIDS; 21(13):0269-9370 [PMID:17690565]
[Connolly N] [Riddler S] [Stanson J] [Gooding W] [Rinaldo CR] [Ferrone S] [Whiteside TL]